abstract Purpose To identify rates of postoperative radiation therapy (RT) after breast conservation surgery (BCS) in women with stage I or II invasive breast cancer treated in Puerto Rico and to examine the sociodemographic and health services characteristics associated with variations in receipt of RT.
INTRODUCTION
The Commonwealth of Puerto Rico is an unincorporated territory of the United States with a population of approximately 3.6 million, primarily of Hispanic origin (98%). Breast cancer is the most common female malignancy in Puerto Rico, 1 and variations in breast cancer outcomes by geographic region and ethnic background 2 exist on the island. In the United States, disparities in the receipt of appropriate radiation therapy (RT) services have been identified, [3] [4] [5] [6] and a lack of appropriate oncologic therapy may contribute to differences in cancer-related health outcomes among racial and ethnic minorities. [7] [8] [9] However, little is known about whether variations in the receipt of guideline-recommended cancer care contribute to disparate breast cancer outcomes among patients in Puerto Rico.
Level I evidence indicates that for some women with early-stage invasive breast cancer treated with breast conservation surgery (BCS), RT reduces the risk of local recurrence and improves overall survival. 13, 14 Thus, the use of RT in this setting has been used consistently as a quality indicator for appropriate oncologic care.
as a viable investigative approach to assessing population-based disparities in the receipt of cancer treatment modalities. However, many studies have used the SEER-Medicare linked databases. [18] [19] [20] The SEER-Medicare databases do not include Puerto Rico, and Hispanics are generally under-represented among the SEER regions that are included. 21 The goal of this study was to use the Puerto Rico Central Cancer Registry (PRCCR)-Health Insurance Linkage Database (HILD) to identify rates of postoperative RT after BCS in women with early-stage invasive breast cancer treated in Puerto Rico and to examine the sociodemographic and health services characteristics that may be associated with variations in receipt of RT.
METHODS

Data Source
We conducted this analysis using the PRCCR-HILD, which links insurance claims files with patients in the PRCCR. The PRCCR is financed by United States federal and state funds, and it covers all 78 municipalities in Puerto Rico. The PRCCR has been part of the United States National Program of Cancer Registries since 1997, and it uses the North American Association of Central Cancer Registries standards for coding data. In 2014, a Centers for Disease Control and Prevention evaluation estimated that for 2012, the completeness of case ascertainment was . 95.0%, comparable to the United States median (98.5%). 22 PRCCR-HILD includes eligibility and claims data for approximately 60% of Puerto Rico's cancer cases for the period 2008 to 2012; these include three of the principal private health insurance carriers and government health plan beneficiaries. Data in the PRCCR files are linked to the insurance claims files via encrypted person identifiers, and all data are de-identified so that no protected health information can be linked to individual patients. The process of linking claims from the health insurance databases was performed using a deterministic match with an algorithm similar to the one used by SEER-Medicare. 23 The MD Anderson Cancer Center and the University of Puerto Rico Medical Sciences Campus institutional review boards approved this study.
Dependent Variables
We determined the proportion of patients who underwent BCS and who received externalbeam RT within 12 months of the breast cancer diagnosis date from the insurance claims. RT and surgery codes are noted in the Data Supplement.
Independent Variables
Independent variables in our analyses included demographic variables (age, geographic area of residence, marital status); diagnostic information (year of diagnosis as defined by the tumor registry); tumor variables (tumor size, nodal involvement); oncologic therapy (surgery type); and insurance type (private insurance, Medicaid, Medicare, or dually eligible). Geographic areas of Puerto Rico were based on Medicaid geographic service regions, as illustrated in Figure 1 .
Statistical Analyses
Statistical analyses were conducted using SAS software (version 9.4; Cary, NC). We performed a Cochran-Armitage test for trend to assess any 
Patient Characteristics
Among the 1,464 women with stage I or II invasive breast cancer who received BCS as their primary definitive treatment 18% were < 49 years old (n = 262), 26% were between 50 and 59 years of age (n = 376), 31% were between 60 and 69 years of age (n = 456), and 25%
Assessed for eligibility (N = 6,348) were > 70 years of age (n = 370). With regard to the distribution of tumor size 28% had tumors , 1.0 cm (n = 409), 42% had tumors . 1.0 cm and < 2.0 cm (n = 619), 28% had tumors . 2.0 cm and < 5.0 cm (n = 412), and 2% had tumors . 5 cm (n = 24). Eighty percent of patients (n = 1,167) had negative pathologic nodal evaluation; however, nodal status was unknown in 6% of patients (n = 84). Fortyone percent of patients (n = 605) were enrolled in Medicaid. Medicare patients and those dually eligible for Medicare and Medicaid represented 20% (n = 288) and 23% (n = 339), respectively. Sixteen percent of patients (n = 232) were covered by private insurance (Tables 1 and 2 ).
RT Receipt After BCS
Among the 1,464 women who received BCS as their primary definitive treatment, 64% were recorded as having received adjuvant RT (Tables 1 and 2 ). Patients older than 70 years of age with tumor size < 2 cm and negative nodes were considered potentially observable after BCS. When these patients were excluded, 63%
received RT. 
DISCUSSION
In our study of women diagnosed with earlystage, invasive breast cancer in Puerto Rico, the rate of RT after BCS was 64%. Our analysis found that Puerto Rican patients enrolled in Medicare and those dually eligible for Medicaid and Medicare were more likely to receive RT after BCS, compared with patients with Medicaid alone. In addition, we identified geographic variations in treatment patterns, with women in the West, Southwest, North, and Metro-North regions more likely to receive RT after BCS.
To our knowledge, this is the first study to evaluate RT use in Puerto Rico; however, previous studies have identified disparate use of RT after BCS in the continental United States. Rates of RT after BCS in nonmetastatic breast cancer are approximately 86% in young women with employer-sponsored health insurance. 25 However, rates have been noted to be as low as 65% in nonwhite women enrolled in Medicare. 26 Specifically, African Americans and Hispanics have been associated with lower rates of RT after BCS compared with non-Hispanic white women. 4 The results of this study suggest underuse of RT in early-stage breast cancer in Puerto Rico that is similar in magnitude to that of ethnic minority populations in the United States. The low rate of RT after BCS is concerning, given that adjuvant RT after BCS reduces the risk of local recurrence and may improve overall survival.
13,14
The reasons for the underuse of RT identified in this study remain to be determined. Prior studies have shown that access to care and socioeconomic factors may influence disparities in breast cancer care in the United States. 27, 28 Other factors, including provider interactions, 29, 30 culturally specific health beliefs, and the presence or absence of social support, 25, 31 could also affect the ability to receive care and may be important variables to explore in future studies seeking to better clarify specific barriers to appropriate breast cancer treatment in Puerto Rico. In addition, previous studies have identified geographic variations in breast cancer care in the United States. 32, 33 Although the reasons for these differences are likely multifactorial, rural and urban differences may play a role in the geographic variations in treatment. Prior studies have demonstrated that rural patients with breast cancer, especially those living farther from RT facilities, are less likely than their urban counterparts to receive guidelinerecommended RT. [34] [35] [36] Detailed information on RT infrastructure, including information regarding the number of RT machines, technologic capabilities, the number of radiation oncologists, and the distribution of resources is not readily available for Puerto Rico. Therefore, the underlying cause of the geographic variations in receipt of RT in Puerto Rico warrants additional evaluation.
Variations in breast cancer treatment by health insurance in the United States have also been reported in past studies. [37] [38] [39] Our finding that women in Puerto Rico insured by Medicare were more likely to receive RT after BCS is in agreement with the findings of previous studies evaluating cancer care in the United States. 9, 38, 40 One possible explanation for this finding may be differences in patient characteristics and patientspecific factors (eg, comorbidities) among insurance plans. In addition, out-of-pocket expenses for a given plan and possible differences in physician recommendations on the basis of reimbursement schedules and incentives provided by health insurance plans could also play a role in the differences seen among insurance carriers.
This study demonstrates the feasibility of the use of the Puerto Rico Cancer Registry in health services research; however, there are several limitations to consider. First, this study does not represent a direct comparison between the population of Puerto Rico and that of the United States. Comparisons can only be inferred on the basis of previously published studies. Future studies could directly compare results from Puerto Rico with representative groups from the United States to better determine the magnitude of RT underuse and to evaluate for unique barriers to care that may exist in Puerto Rico. Second, not all insurance payers are currently linked to the PRCCR-HILD databases, limiting the scope and generalizability of the analysis. In particular, private payers are under-represented in the current analysis. PRCCR is currently working to expand the number of private insurance carriers available in the PRCCR-HILD, and future studies should be able to better identify the differences between private and public payers. Third, insurance Hypofractionation has the potential to be a powerful tool in addressing disparities in communities with limited access to radiation oncology resources, and adoption of hypofractionation techniques in Puerto Rico will be an important area of future study. Finally, comorbidity indices were not determined because of the limited numbers of patients with 12 months of claims before diagnosis and because of the inability to definitively confirm insurance enrollment status. Unaccounted-for differences among the study groups may exist, which may have influenced our reported outcomes.
In conclusion, our findings have the potential to significantly influence oncologic care in Puerto Rico by directing attention to the underuse of guideline-concordant care for early-stage breast cancer. Future studies should focus on better elucidating the barriers to cancer care and possible relevant interventions, including the use of hypofractionation techniques, intraoperative RT, and omission of RT for selected patients. In addition, this study is particularly timely, given the current economic and health care crisis in Puerto Rico. It is hoped that a more accurate definition of the current use of oncologic services will encourage policy experts to make informed decisions during any potential restructuring of governmental and health care resources. 
